 Original research
 Open Access
 Published:
Feasibility of simplifying renal dosimetry in ^{177}Lu peptide receptor radionuclide therapy
EJNMMI Physics volume 5, Article number: 12 (2018)
Abstract
Background
Recently, ^{177}Ludotatate therapy for neuroendocrine tumours has received regulatory approval. Dosimetry can be used to optimize treatment on an individual basis, but there is no international consensus as to how it should be done.
The aim of this study is to determine a feasible and accurate dosimetry method to guide individualized peptide receptor radionuclide therapy (PRRT) for patients with neuroendocrine tumours.
As part of a clinical trial on ^{177}Ludotatate therapy, renal dosimetry was performed for all patients in each treatment cycle, using a hybrid planarSPECT/CT method. In the present study, we use the image data acquired from 22 patients and 119 cycles and define a set of alternative treatment planning strategies, each representing a simplification in terms of image acquisition and dosimetric calculations. The results from the simplified strategies are compared to the results from the protocolprescribed hybrid planarSPECT/CTbased method by analysing differences both in percycle and total cumulative absorbed dose (AD) analyses.
Results
In general, the SPECTbased methods gave results that were largely consistent with the protocolspecified hybrid method, both in the percycle and cumulative AD analyses. Notably, performing one SPECT/CT per cycle at 96 h yielded ADs that were very similar to the protocol method. The methods using planar dosimetry resulted in larger variations, as expected, while giving 4 cycles to all patients resulted in the largest interindividual differences in cumulative AD.
Conclusions
Performing one SPECT/CT at 96 h in every treatment cycle gives sufficiently reliable dosimetric results to base individualized treatment planning on, with a reasonable demand on resources.
Background
Peptide receptor radionuclide therapy (PRRT), an established treatment for neuroendocrine tumours (NET), has recently received regulatory approval based on the results from the randomized phase III trial NETTER1 [1]. Further optimization of PRRT may be achieved not only through improved patient selection with the use of clinical criteria [2], imaging [3] and molecular analyses[4] but also through improving the way the treatment is planned and carried through. The optimization strategies differ from centre to centre and include, but are not limited to, combining PRRT with chemotherapy [5, 6], combining different radionuclides [7] and using dosimetry to personalize treatment [8], the latter being the method of choice by our groups.
In external beam radiotherapy and brachytherapy, it is standard procedure to individually plan treatment by calculating absorbed dose (AD) to both target (i.e. tumour) and organs at risk, with the aim of optimizing the AD delivery so as to achieve a high probability of antitumour effect with a low risk as reasonably achievable of serious toxicity. This concept can also be applied to systemic radiotherapy such as PRRT, although there is as of yet no international consensus on how this should be done.
Our groups have, over the past several years, systematically worked to improve methods and clinical applications in the realm of dosimetryguided systemic radiotherapy, with the longterm aim of improving treatment planning and results [9,10,11,12,13,14,15,16,17]. As part of this development, we designed a phase II trial (NCT01456078, “Iluminet”) to investigate the feasibility, safety and efficacy of individualized PRRT based on patient selection and dosimetry. The trial has been approved by the institutional ethics committee (ref. no. 2011/287) and national regulatory authorities. Further details on the protocol can be found at www.clinicaltrials.gov. All patients have given their written informed consent to participate.
In the Iluminet trial, the hypothesis was that by using individualized treatment planning, the balance between treatment effect and toxicity is optimized. Patients with advanced, progressive NET were treated with 7400 MBq ^{177}Ludotatate at 8–12week intervals, and detailed posttherapeutic imaging and dosimetry were performed in all patients after every cycle. The number of cycles each patient received was determined by a combined evaluation of dosimetry, treatment effect and toxicity. Patients with risk factors for nephrotoxicity received treatment up to a cumulative renal biologically effective dose (BED) of (27 ± 2) Gy, and patients without such risk factors were offered to continue up to (40 ± 2) Gy. This individualized approach led to a wide range in the number of cycles per patient, differing substantially from the standard four treatment cycles [18].
The dosimetric method used per protocol in the Iluminet trial is a hybrid planarSPECT/CT method, where the timeretention curve is derived from serial planar images, and the absorbed doserate information from a SPECT/CT is used for rescaling into a timedose rate curve. Performing such dosimetry for each cycle is timeconsuming both for the patients and for the therapeutic team of technologists, physicists and physicians. In the context of a prospective clinical trial exploring the feasibility of individualized, dosimetrybased treatment planning, it is justified to use such a complex method. However, if this concept is to be brought to clinical routine, it is of interest to determine whether simplifications can be made without substantially affecting the estimated ADs.
In the present study, we use the image data acquired during the trial and define a set of alternative treatment planning strategies, each representing a simplification in terms of image acquisition and dosimetric calculations. The alternative strategies include the current standard of 4 cycles to all patients, planar dosimetry, simplified hybrid dosimetry and dosimetry based on one SPECT/CT only. Additionally, we have applied the method proposed by Hänscheid et al. [19] of using one single measurement after 4 days for both planar and SPECT/CT data. The results from the simplified strategies are compared to the results from the protocolprescribed hybrid planarSPECT/CTbased method and are evaluated both in terms of percycle differences as well as the cumulative absorbed dose over all cycles.
Thus, the aim of the work presented in this paper is to investigate the ADs that are obtained when simplified treatment strategies or dosimetry schemes are used as alternatives to the more complex protocolprescribed method, in order to make conclusions of possible simplifications for future dosimetrybased ^{177}LuPRRT.
Methods
The image data on which the present analyses are based include the same patients as in the previously published interim analysis of the Iluminet trial [18]. Of the 51 patients that had been included at the time of the interim analysis, 22 had completed treatment as planned, i.e. had reached the targeted BED to the kidneys. It is on this subset of patients that the present analyses have been performed, comprising dosimetry of 119 cycles in total.
Patient image acquisitions
The clinical trial protocol included patient imaging and kidney dosimetry in each cycle. Four anteriorposterior (AP) wholebody images were acquired at nominal times of 1, 24, 48 or 96 h (depending on which weekday the patient received treatment), and 168 h post administration, and one SPECT/CT study was performed at 24 h. An Xray scout image was also acquired at 24 h to serve as attenuation map for wholebody image activity quantification.
Being a twocentre study, acquisitions were performed using a variety of camera systems (see Table 1. For wholebody scans, the matrix size was 1024 × 256 and the pixel size 2.2 × 2.2 mm^{2}. Acquisition times were 10 or 20 min for the image at 1 h and 20 min for the other time points. SPECT projections were acquired using 60 projections over 360°, each of 45 s. The matrix size was 128 × 128 and the pixel dimensions approximately 4 × 4 mm^{2}. For each of the gamma camera systems, the calibration factor was determined by measuring the system sensitivity for ^{177}Lu in air, following established procedures [20], i.e. the count rate obtained in a planar image in response to a thin layer of ^{177}Lusolution placed in a Petri dish. The same calibration method was used for planar and SPECT images. Crosscalibration and traceability of the activitymeter readings at the two centres had previously been established using a source of ^{177}Lu with activity statement from the National Physical Laboratory, UK. CT image acquisitions were performed using 120 kV and a lowdose protocol with either 2 mA or a current setting based on a noise index.
Quantification of activity, AD and BED
The procedure for imagebased dosimetry is summarized in Fig. 1.
The dosimetry calculations were performed using a program package called LundADose, implemented in the IDL programming language (Harris Geospatial Solutions, Broomfield, CO, USA). Prior to the actual computations, patient images were exported from the respective gamma camera systems, in DICOM image format, to the Interfile 3.3 format used internally in LundADose.
The planar images were processed using a pixelbased implementation of the conjugateview method, as previously reported [21, 22]. In the processed wholebody images from the four time points, regions of interest (ROIs) over the left and right kidneys were delineated, as well as a background ROI below each kidney (Fig. 2). Since the main purpose of the planarbased values was to determine the shape of the renal timeactivity curve rather than the total kidneyactivity content, it was not necessary that the ROIs encompassed the whole kidneys. Instead, care was taken to avoid overlapping tissues such as the liver or tumours. In cases when one kidney was severely overlapped by extrarenal activity uptakes, the effective halftime from the least overlapped kidney (often left) was used as an estimate also for the contralateral kidney. Background correction was accomplished by determining the activity per pixel in the respective background ROIs and then scaling to the number of pixels in the kidney ROIs, as well as to an estimated thickness of the background compartment within the kidney ROI [22].
Voxelwise SPECT activity quantification was achieved as part of an iterative orderedsubsets expectation maximization image reconstruction, including corrections for attenuation and scatter, using a modelbased method [23] and collimator response, and employing eight iterations and ten subsets. In order to use the CT image for attenuation and scatter corrections, the CT image values were first converted to mass density using a calibrationphantombased relationship, as previously described [21]. From the density map, an attenuation map was generated by multiplication to mass attenuation coefficients valid for the soft tissue and cortical bone, for 208 keV. The quantitative SPECT image and the CTderived massdensity image were used as basis for a Monte Carlo voxelbased doserate calculation using the EGS4/PRESTA algorithm [24]. Volumes of interest (VOIs) were drawn, by specialized technologists, along the kidney contour in the SPECT/CT images, mainly by guidance from the transversal CT. The VOIs were applied to the 3D absorbeddose rate images, and the median absorbeddose rate in the VOI was determined. This value was then divided by a recovery factor of 0.85, which had been established in a previous study where manual segmentation was performed by several operators in Monte Carlosimulated SPECT/CT images [25]. This value of 0.85 was thus considered valid for all patient kidneys using the chosen methodology for image segmentation and SPECT image reconstruction.
A series of timedose rate values at different times, R(t), were derived by combining the SPECTderived absorbeddose rate acquired at t_{S}, i.e. R(t_{S}), with the planarderived activity values from different time points, A_{P}(t), according to
A curve, consisting of an initial straight line followed by a trailing monoexponential function, was fitted to timedose rate values. The monoexponential function was fitted to the three last data points using weighted least squares, and the initial line was then determined analytically based on the values of the monoexponential function at the time of the second data point and the first data point. This curve shape, in particular the initial straight line (equivalent to a trapezoid integration), was used as the simplest approach, realizing that the true, underlying renal timeactivity curve, including the very fast initial redistribution [16, 26], was not resolvable from the two data points acquired during the first 24 h. The AD was determined as the area under the curve, calculated by analytical integration. Finally, the absorbeddose rate curve was used as input to the calculation of the BED using a convolutionbased method [12] with radiobiologic parameters α/β of 2.6 Gy and a repair halftime of 2.8 h [27].
The decision of whether the patient was to receive further treatment cycles was based on an overall evaluation of the cumulated renal BED, the projected renal BED in case of further treatment in relation to the target BED (27 or 40 Gy) as well as tumour effect and toxicity of treatment thus far.
Simplified treatment strategies and dosimetry methods
Nine different, alternative treatment planning strategies were defined (see summary in Table 2). The hybrid dosimetry method used in the Iluminet trial is referred to as method P (for protocol) and is described in detail above.

A.
Four cycles to all patients. The current standard treatment regimen, without patientspecific tailoring. For each patient and each cycle, the leftright mean renal AD was determined using method P, and the data for the four first cycles were summed. For patients who had only been given 3 cycles, the AD of a fourth cycle was set equal to that of the third cycle.

B.
Planarbased dosimetry with four wholebody acquisitions during the first cycle only. The conjugateview method was used to calculate the renal activity from the anteriorposterior planar images. A more typical implementation was here used such that ROIs encompassing the whole kidneys were delineated in the acquired count images, as well as background ROIs to subtract activity contributions from background tissues. In some cases, where the right kidney was extensively overlapped by the liver, the effective halftime estimated for the left kidney was used as a surrogate. The kidney mass was estimated by delineation in a CT image, and the dosefactor values (DFs) retrieved from OLINDA/EXM [28]. The leftright mean renal AD was determined for the first cycle. For the following cycles, it was assumed that the AD per administered activity remained unchanged. The AD for cycle n was calculated by multiplication to the ratios of administered activities, thus also taking small deviations from the nominal 7400 MBq into account, according to

C.
Planarbased dosimetry with four wholebody acquisitions in each cycle. Planar image quantification was applied as in B. For each of the treatment cycles, the leftright mean renal AD was taken and the cumulative AD was calculated as the sum of the ADs/cycle.

D.
Hybrid dosimetry in the first cycle only, i.e. four wholebody acquisitions and one SPECT at 24 h. The ADs for the following cycles were calculated using Eq. 5.

E.
Hybrid dosimetry in the first cycle, and one SPECT/CT at 24 h each cycle thereafter. The AD contribution for cycle n was here calculated by multiplication of the AD for cycle 1, to the ratios of SPECTderived absorbed dose rates. The AD was determined as the mean of the left and right kidney ADs. For instance, the AD for the left kidney and cycle n, D_{L, n}, was obtained using
The exponential function was here included to take into account possible differences in the time of the SPECT/CT acquisition for the different cycles, where the effective decay constant, λ_{L, 1}, was obtained from the first cycle.

F.
One SPECT/CT at 24 h in each cycle, identical effective halftime for all patients assumed. The shape of the timeactivity curve was assumed to be identical and monoexponential for all patients and was described by a decay constant, λ_{ref}, based on the mean effective halftime of 51.6 h obtained in a previous study [18]. Also in this case, the AD for cycle n was determined as the mean of the left and right kidney ADs, where, for instance, for the left kidney, the AD was calculated as

G.
One SPECT/CT at 96 h in each cycle. It was considered of interest to evaluate the simplification of using one SPECT/CT acquired at 4 days, as suggested in a recent publication [19]. Since the SPECT/CT was in most of our patients acquired on day 1, the absorbeddose rate at 96 h was estimated by extrapolation using the effective halftime of the individual patient and kidney. The AD for cycle n was determined as the mean of the left and right kidney ADs, where, for instance, for the left kidney, the AD was calculated according to
where t_{ref} was thus 96 h [19].

H.
One SPECT/CT at 96 h in the first cycle only. The AD for the first cycle was estimated as in alternative G, and for the following cycles using Eq. 5.

I.
One planar image at 96 h in each cycle. The AD was estimated as in alternative G, but the factor R was obtained from planar images rather than SPECT.
Data analysis
Systematic and random differences in the estimated AD per cycle between methods B to I and the protocol method P were investigated using BlandAltman analysis [29]. The relative difference in AD between the alternative method and the reference method was compared to the mean AD of the two methods. The standard deviation (SD) was estimated based on a oneway analysis of variance [30], i.e. the variation of differences in estimated AD was assumed to be the result of a combination of inter and intrapatient variability. Results were summarized quantitatively in terms of the Limits of Agreement (LOAs) that were defined as the average difference ± 2SD. Method A was not included in the BlandAltman analysis as the AD/cycle used was in this case determined using the reference method (P).
The effect of the different treatment planning strategies on the final cumulative AD was also analysed. For each patient, the leftright mean renal AD was calculated for each cycle and then summed over the actually given number of cycles. For method A, the ADs for the first 4 cycles given were summed. The cumulative AD for each alternative method was set in relation to the AD for the protocolspecified dosimetry method. In order to be able to conclude which methods would have given an equivalent cumulative AD, an analysis of the uncertainty in the AD/cycle for the protocol method was done (see Additional file 1), giving an estimated fractional uncertainty of 10% (1SD). The uncertainty in the cumulative AD from multiple cycles was calculated using the law of propagation of uncertainty [31]. As information on the covariance in the AD estimates between cycles was not available, it was not considered in the uncertainty propagation. The confidence interval (CI) of the protocolspecified dosimetry was estimated as the cumulative absorbed dose ± 2SD.
Since method G was considered of particular interest (see the “Results” section) and we had access to SPECT/CT in six patients at four time points, a small additional analysis was made in which the AD resulting from method G was compared to the AD determined from four SPECTs/CT (see Additional file 1).
Results
Percycle analysis
The results of the BlandAltman analysis of the percycle AD of the alternative dosimetry methods B–I vs the protocolspecified dosimetry method are shown in Fig. 3. None of the methods studied resulted in marked systematic differences in the mean AD/cycle. The planarbased methods (B, C and I) resulted in the largest random differences with LOAs of − 3 ± 51%, 6 ± 43% and 8 ± 45%, respectively. Performing dosimetry in the first cycle and none thereafter also yielded wide LOAs of − 3 ± 36% with method D (hybrid dosimetry method) and − 2 ± 39% when applying Eq. 8 (method H). Using method F, i.e. one SPECT/cycle at 24 h, and a constant value of the effective halftime (51.6 h), the LOAs were − 2 ± 25%, while when using SPECT/CT hybrid dosimetry in the first treatment cycle and one SPECT/cycle in subsequent cycles (method E), LOAs were 1 ± 17%. The method whose results were most consistent with those achieved using the protocolspecified dosimetry method was method G (one SPECT/cycle at 96 h and application of Eq. 8) resulting in LOAs of 1 ± 11%.
Cumulative absorbed dose analysis
Results of the comparisons of the total cumulative AD with methods A–I vs the AD achieved with the protocolspecified dosimetry method (± 2SD) are shown in Table 3. Giving 4 cycles to all patients (method A) yielded ADs that were consistent with dosimetrybased treatment in 4/22 (18%) patients, i.e. there were four patients who received 4 cycles when treated according to protocol. Planar dosimetry first cycle only (method B) and in all cycles (C and I) were consistent with method P in 3/14 (21%), 6/14 (43%) and 4/14 (29%) patients, respectively. SPECTbased dosimetry first cycle only (methods D and H) yielded consistency in 11/22 (50%) and 7/22 (32%) patients, respectively. The methods including SPECT in each cycle (E, F and G) were consistent with the reference ADs in 20 (91%), 19 (86%) and 22 (100%) of the 22 patients, respectively.
The practical consequences of using one method or another can be illustrated by a few patient examples: patient 1 received seven treatment cycles (27 Gy) in the protocol. Had we used planar dosimetry (method B or C), we would have overestimated the dose/cycle and interrupted treatment prematurely. Had the patient received only 4 cycles, the cumulative renal AD would have been 16 Gy. Patient 2 had an obstructive nephrolithiasis shortly after receiving cycle 2 resulting in a very high AD to the left kidney. In such a case, an estimated AD based on cycle 1 (methods B and D) would have underestimated the actual AD delivered. Hypothetically, if treatment would have been given based on method B or D, the patient would have received another 1 to 2 cycles resulting in an extrapolated total renal AD of 30 to 40 Gy, potentially causing further damage to the patient’s kidneys. Dosimetry in each cycle is helpful in determining a safe number of cycles for the continued treatment in such cases. Patient 14 is also an example of deviation from the expected in the sense that the halftime differed from the mean to such an extent that method F, which in most cases gave an acceptable result, would have led to a considerable underestimation of the AD/cycle. On the other hand, using method G in all patients would have reduced the number of imaging time points by 75% (once instead of four times) and the time spent for imaging by approximately 67% (from 120 to 40 min). From the small comparative analysis with four SPECTs/CT per cycle (Additional file 1), method G yielded deviations comparable to those obtained using the hybrid method, with a maximum deviation of − 11%.
Discussion
The overall aim in this study was to elucidate whether it is possible to use a less demanding treatment strategy or dosimetry method in individualized ^{177}Ludotatate therapy, as compared to that used in the ongoing clinical trial (Iluminet), while maintaining a similar degree of accuracy in renal AD estimates.
For the clinical trial protocol, a hybrid dosimetry method has been used. This choice was a compromise between the axial coverage offered by the wholebody planar images, and the superior accuracy of SPECT/CT. Moreover, at the time of the writing of the clinical trial protocol, performing serial SPECTs in each cycle, including the subsequent processing and analysis of 3D images, was deemed too timeconsuming to be feasible.
For the evaluation of the AD per cycle for the alternative treatment strategies (Fig. 3), we conclude that the dosimetry methods in which SPECT/CT are included are superior to the purely planarbased methods and that including one SPECT/CT in each cycle improves the dosimetric accuracy considerably. Results based on the cumulative AD (Table 2) are consistent with results from the percycle analysis. Dosimetry method G, including one SPECT/CT in each cycle at 96 h, yields results that are equivalent with the protocol dosimetry method P but with much lower demands on resources. Methods E and F, which also use SPECT in every cycle, give similar but slightly less consistent results.
Method G was implemented following the original work by Hänscheid et al. [19], where an approximate method for estimation of the area under the timeactivity curve based on one single image acquisition was developed. The approximation can be derived from the expression of the absorbed dose for a monoexponential curve, following
where the last, approximate equality is exact when the imaging time is equal to the effective halftime (t_{ref} = T_{1/2}) or two times the effective halftime (t_{ref} = 2 T_{1/2}). Hänscheid et al. [19] noted that the righthand expression yields valid approximations when 0.75 T_{1/2} < t_{ref} < 2.5 T_{1/2} and in particular when t_{ref} = 96 h. If we denote the righthand term as \( \widehat{D}, \) the theoretical fractional error, E_{1}, becomes
with f = t_{ref}/T_{1/2}. Figure 4 shows the theoretical fractional error, E_{1}, as a function of t_{ref} for an effective halftime 51.6 h, as obtained in a previous study [18]. It was considered of interest to evaluate the fractional error for patient data for different choices of t_{ref}. Moreover, since in practice the imaging time point cannot be tuned to the effective halflife for a specific patient and cycle, for a given choice of t_{ref}, the dispersion in effective halftimes will translate into a variance in the fractional error. The data underlying results in Fig. 3 (method G) were thus reanalysed to a patientbased fractional error, E_{2} = (D_{G} − D_{P})/D_{P} , where D_{G} and D_{P} are the absorbed doses obtained from method G and P, respectively. Figure 4 shows the mean value of E_{2} obtained over all patients and cycles, the SD around the mean and the rootmean square deviation (RMSD) in E_{2}, when the value of t_{ref} in Eq. 8 is varied between 24 and 144 h. It appears that the theoretical fractional error (E_{1}) compares well with the fractional error obtained for patients (mean of E_{2}) and that the overall deviation, as described by the RMSD, contains both systematic (mean of E_{2}) and random components (SD of E_{2}). When the dispersion in effective halftimes is comparably modest, as for the kidney data analysed herein, the RMSD exhibits a valley when T_{1/2} < t_{ref} < 2T_{1/2} and is lowest near 96 h (t_{ref} ≈ 2T_{1/2}). For an imaging time near 50 h (t_{ref} ≈ T_{1/2}), the systematic component of the error is equally low as for 96 h, while the SD is higher, thus yielding a slightly higher RMSD. The RMSD is also more sensitive to the exact acquisition time at 50 h than at 96 h. Thus, acquisition at approximately 4 days appears to be a valid choice for this approximation. This is also confirmed by the uncertainty analysis based on SPECT/CT on day 4 (Additional file 1), where method G yields ADs that are equivalent to the protocol results. One drawback with our evaluation of method G is that the effective halftime estimated for the individual patient is included in the calculation of the absorbeddose rate at 96 h since our SPECT/CTs were not acquired at 96 h. However, we still find it motivated to perform an independent evaluation of this new method, and the included implementation is deemed to be the fairest.
The comparably small deviations obtained using method F, i.e. one SPECT/CT for each cycle and a standard effective halftime for all patients, were unexpected and prompted further investigation. Figure 5 shows data derived from a larger patient material (80 subjects) than the one used for the analyses above. From this figure, we see that the shape of the timeactivity curves after 24 h (A and B) as described by the effective halftime (C) is similar between patients, the median being 51.7 h. It is possible, however, that this uniformity in effective halftime is partly due to the uniformity of patient selection and procedures dictated by the clinical trial protocol. It would be of interest to perform a similar analysis in a reallife setting and in different PRRT centres. The vast spread in the first data point in the timeactivity curve is a result of the imaging being performed at a time when there is a fast initial turnover and washout of ^{177}Ludotatate via the kidneys [26]. This thus supports the choice of fitting function where the first data point, acquired at approximately 1 h, is decoupled from the fitting of the exponential tail and is thus not allowed to influence the assessment of the effective halftime. In spite of the vast spread observed, the AD using method F is in most cases consistent with the protocol dosimetry method P. This is explained by results in Fig. 5d where it is observed that the majority of the AD is delivered after the first 24 h (left kidney median 76% (interquartile range 73 and 79%), right kidney median 75% (interquartile range 72 and 79%)).
The conversion from activity to absorbeddose rate is, according to the clinical protocol, performed using Monte Carlobased radiationtransport calculation in a voxelized geometry. Since the range of the electrons emitted from ^{177}Lu is shorter than the spatial resolution of the SPECT images, the radiationtransport calculation could possibly have been simplified to a multiplication by the assumption that the electron kinetic energy is absorbed locally in the voxel [24]. However, it was considered important not to neglect the photon contribution, since parts of the kidneys are located near organs with high uptake such as the spleen, and since in addition to gamma radiation, there are also lowenergy Xrays emitted in the ^{177}Lu decay that contribute to the selfabsorbed dose. The Monte Carlo method was considered the best choice based on accuracy and availability. Notably, given that only one SPECT/CT is available, it is assumed that the fractional contribution from photons to the total absorbed energy in the kidneys is constant during the entire treatment cycle, whereas in reality, the photon contribution varies with time depending on the activity present in surrounding tissues.
When attempting a conclusion from these results, we can look at them from two different angles. From a methodological point of view, we want the most accurate method to be used, while from a clinical perspective, the question is how much accuracy is really needed in relation to the observed efficacy and toxicity. Of the methods compared in this analysis, dosimetry as per protocol is presumably the most accurate one (as the rest are simplifications of the same), but doing four SPECTs/CT in each cycle would probably yield even more accurate results although to the price of a more timeconsuming procedure. Among the simplified methods analysed, we would choose the one with the smallest mean difference for each cycle and the narrowest LOAs.
The methods which best fit these criteria are E and G, both of which incorporate SPECTbased dosimetry in every cycle but are less resourceintense than the reference method P. The strategy that deviates the most is unequivocally method A, i.e. giving 4 cycles to all patients, followed by the planarbased dosimetry methods (B, C and I). This is consistent with what is already known about the drawbacks of planar dosimetry, namely the difficulties in taking into account individual variations in activity concentration, especially in tumours, the liver and intestines, which may then lead to over or underestimation of the renal AD.
When choosing between methods E and G, one aspect to take into account is that for most PRRT centres, it would be more resourceconsuming to perform a SPECT at 96 h since the patients would have to come back to the hospital. Whether or not to still go for method G then becomes a matter of whether or not the small difference seen in the BlandAltman analyses (2SD of 11 and 17% for methods G and E, respectively) makes a relevant difference in reallife patient management.
From a clinical perspective, on the other hand, some would argue that to give 4 cycles to all patients is already a very effective treatment with a low degree of toxicity, so the need for further optimization is marginal. There are two objections to this: firstly, our obligation to know what we are doing when employing radiation for therapeutic purposes (analogous to the demands in other radiation therapy modalities), and secondly, when these patients progress months or years after their 4 cycles of PRRT, we would like to retreat them since the majority of the cases have not reached the limits for the organs at risk. Without initial dosimetric estimates, we have no grounds on which to plan further treatment.
Given the highly clinically and statistically significant effect of PRRT demonstrated in the NETTER1 trial [1], together with the ample experience and long safety followup with the standard 4 cycles of treatment, perhaps the optimal treatment strategy is a mix between this and dosimetrybased treatment. This could be achieved by initially giving 4 cycles to all (or less if tolerance limits are reached before), but performing dosimetry as well. When the tumour later progresses, the patient can be retreated to risk organ tolerance limits. In this manner, we get a good riskbenefit balance at each stage of the disease—early in the disease when the patient has a longer expected survival, we use a lowrisk treatment, but once progression has been confirmed and the prognosis is another, it is more reasonable to assume the possible risks of higher ADs to risk organs associated with further treatment. Even with the relatively high renal BED limits used in the Iluminet trial, the toxicity has so far been limited (unpublished data), so it is still an open question which limits we should use in the future. Perhaps further retreatment beyond the limits used in this trial will be feasible for some patients under certain conditions. For this reason also, it will be of essence to incorporate dosimetry in PRRT planning, both in clinical routine and future clinical trials, and thereby progressively increase our understanding and body of knowledge.
Conclusions
From a methodological and clinical point of view, we need an accurate dosimetric method demanding a reasonable amount of resources. Dosimetry based on one SPECT/cycle complies with these requirements, and it seems that performing the SPECT at 96 h gives reliable results.
Abbreviations
 AD:

Absorbed dose
 AP:

Anteriorposterior
 BED:

Biologically effective dose
 CT:

Computed tomography
 LOAs:

Limits of agreement
 NET:

Neuroendocrine tumour
 PRRT:

Peptide receptor radionuclide therapy
 ROIs:

Regions of interest
 SD:

Standard deviation
 SPECT:

Singlephoton emission computed tomography
 VOI:

Volume of interest
References
 1.
Strosberg J, ElHaddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Ludotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35. https://doi.org/10.1056/NEJMoa1607427.
 2.
Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Longterm tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5–19. https://doi.org/10.1007/s0025901428935.
 3.
Ezziddin S, Lohmar J, YongHing CJ, Sabet A, Ahmadzadehfar H, Kukuk G, et al. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate? Clin Nucl Med. 2012;37:e141–7. https://doi.org/10.1097/RLU.0b013e31823926e5.
 4.
Bodei L, Kidd M, Modlin IM, Severi S, Drozdov I, Nicolini S, et al. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2015. doi:https://doi.org/10.1007/s002590153250z.
 5.
Claringbold PG, Price RA, Turner JH. Phase III study of radiopeptide 177Luoctreotate in combination with capecitabine and temozolomide in advanced lowgrade neuroendocrine tumors. Cancer Biother Radiopharm. 2012;27(9):561. https://doi.org/10.1089/cbr.2012.1276.
 6.
Barber TW, Hofman MS, Thomson BN, Hicks RJ. The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. Eur J Surg Oncol. 2012;38:64–71. https://doi.org/10.1016/j.ejso.2011.08.129.
 7.
Villard L, Romer A, Marincek N, Brunner P, Koller MT, Schindler C, et al. Cohort study of somatostatinbased radiopeptide therapy with [(90)YDOTA]TOC versus [(90)YDOTA]TOC plus [(177)LuDOTA]TOC in neuroendocrine cancers. J Clin Oncol. 2012;30:1100–6. https://doi.org/10.1200/JCO.2011.37.2151.
 8.
Sandstrom M, GarskeRoman U, Granberg D, Johansson S, Widstrom C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177LuDOTAoctreotate treatment. J Nucl Med. 2013;54:33–41. https://doi.org/10.2967/jnumed.112.107524.
 9.
Ljungberg M, Frey E, Sjogreen K, Liu X, Dewaraja Y, Strand SE. 3D absorbed dose calculations based on SPECT: evaluation for 111In/90Y therapy using Monte Carlo simulations. Cancer Biother Radiopharm. 2003;18:99–107. https://doi.org/10.1089/108497803321269377.
 10.
Ljungberg M, Sjogreen K, Liu X, Frey E, Dewaraja Y, Strand SE. A 3dimensional absorbed dose calculation method based on quantitative SPECT for radionuclide therapy: evaluation for (131)I using Monte Carlo simulation. J Nucl Med. 2002;43:1101–9.
 11.
Garkavij M, Nickel M, SjogreenGleisner K, Ljungberg M, Ohlsson T, Wingardh K, et al. 177Lu[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116:1084–92. https://doi.org/10.1002/cncr.24796.
 12.
Gustafsson J, Nilsson P, Gleisner KS. On the biologically effective dose (BED)using convolution for calculating the effects of repair: II. Numerical considerations. Phys Med Biol. 2013;58:1529–48. https://doi.org/10.1088/00319155/58/5/1529.
 13.
Gleisner KS, Brolin G, Sundlov A, Mjekiqi E, Ostlund K, Tennvall J, et al. Longterm retention of 177Lu/177mLuDOTATATE in patients investigated by gammaspectrometry and gammacamera imaging. J Nucl Med. 2015;56:976–84. https://doi.org/10.2967/jnumed.115.155390.
 14.
Larsson M, Bernhardt P, Svensson JB, Wangberg B, Ahlman H, ForssellAronsson E. Estimation of absorbed dose to the kidneys in patients after treatment with 177Luoctreotate: comparison between methods based on planar scintigraphy. EJNMMI Res. 2012;2:49. https://doi.org/10.1186/2191219X249.
 15.
Svensson J, Molne J, ForssellAronsson E, Konijnenberg M, Bernhardt P. Nephrotoxicity profiles and threshold dose values for [177Lu]DOTATATE in nude mice. Nucl Med Biol. 2012;39:756–62. https://doi.org/10.1016/j.nucmedbio.2012.02.003.
 16.
Brolin G, Gustafsson J, Ljungberg M, Gleisner KS. Pharmacokinetic digital phantoms for accuracy assessment of imagebased dosimetry in (177)LuDOTATATE peptide receptor radionuclide therapy. Phys Med Biol. 2015;60:6131–49. https://doi.org/10.1088/00319155/60/15/6131.
 17.
Gustafsson J, Brolin G, Cox M, Ljungberg M, Johansson L, Gleisner KS. Uncertainty propagation for SPECT/CTbased renal dosimetry in (177)Lu peptide receptor radionuclide therapy. Phys Med Biol. 2015;60:8329–46. https://doi.org/10.1088/00319155/60/21/8329.
 18.
Sundlov A, SjogreenGleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, et al. Individualised 177LuDOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44(9):1480. https://doi.org/10.1007/s0025901736784.
 19.
Hänscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose mapping after endoradiotherapy with 177LuDOTATATE/TOC by one single measurement after four days. J Nucl Med 2017. doi:https://doi.org/10.2967/jnumed.117.193706.
 20.
NEMA. NU 12012 performance measurements of gamma cameras. Rosslyn, Virginia: NEMA Standards Publication; 2012.
 21.
Sjögreen Gleisner K, Ljungberg M. Patientspecific wholebody attenuation correction maps from a CT system for conjugateviewbased activity quantification: method development and evaluation. Cancer Biother Radiopharm. 2012;27:652–64. https://doi.org/10.1089/cbr.2011.1082.
 22.
Sjogreen K, Ljungberg M, Strand SE. An activity quantification method based on registration of CT and wholebody scintillation camera images, with application to 131I. J Nucl Med. 2002;43:972–82.
 23.
Frey EC, Tsui BMW. A new method for modeling the spatiallyvariant, objectdependent scatter response function in SPECT. 1996 IEEE Nuclear Science Symposium. Annaheim: IEEE; 1996. p. 1082–6. https://doi.org/10.1109/NSSMIC.1996.587906.
 24.
Ljungberg M, SjogreenGleisner K. The accuracy of absorbed dose estimates in tumours determined by quantitative SPECT: a Monte Carlo study. Acta Oncol. 2011;50:981–9. https://doi.org/10.3109/0284186X.2011.584559.
 25.
Mortensen N, Morin K, Hermann R, Brolin G, Gustafsson J, Sundlöv A, et al. Interoperator variability in manual image segmentation and its impact on the renal absorbed dose and biologically effective dose in 177LuDotatate therapy. Eur J Nucl Med Mol Imaging. 2014;41(Suppl. 2):S259.
 26.
Delker A, Ilhan H, Zach C, Brosch J, Gildehaus FJ, Lehner S, et al. The influence of early measurements onto the estimated kidney dose in [(177)Lu][DOTA(0),Tyr(3)]octreotate peptide receptor radiotherapy of neuroendocrine tumors. Mol Imaging Biol. 2015;17:726–34. https://doi.org/10.1007/s1130701508393.
 27.
Thames HD, Ang KK, Stewart FA, van der Schueren E. Does incomplete repair explain the apparent failure of the basic LQ model to predict spinal cord and kidney responses to low doses per fraction? Int J Radiat Biol. 1988;54:13–9.
 28.
Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the secondgeneration personal computer software for internal dose assessment in nuclear medicine. JNuclMed. 2005;46:1023–7.
 29.
Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307–10.
 30.
Searle SR, Casella G, McCulloch CE. The 1way classification. In: Variance components. Hoboken: Wiley; 1992. p. 44–111.
 31.
Evaluation of measurement data—guide to the expression of uncertainty in measurement. JCGM 100:2008. GUM 1995 with minor corrections. JCGM member organizations (BIPM, IEC, IFCC, ILAC, ISO, IUPAC, IUPAP and OIML). 2008.
Acknowledgements
The authors wish to acknowledge the contribution to this work from medical physicists Cecilia Hindorf and Erik Larsson, technologist Karin Morin and research nurses Charlotte Fogelström and Kajsa Holgersson.
Funding
This trial was made possible by research grants from the Swedish Research Council (grant no. 62120146187), Swedish Cancer Society, Mrs. Berta Kamprad’s Foundation (BKS 201551 and BKS 201737), Gunnar Nilsson’s Foundation, Swedish Radiation Safety Authority and Jubilee Clinic Cancer Research Foundation and the Swedish Federal Government under ALF agreement.
Availability of data and materials
At this point, the trial on which these analyses are based is still active. Data will be made publicly available once the trial has completed the inclusion and followup, the data has been monitored and the database has been locked. Until then, the data may be made available on demand.
Author information
Affiliations
Contributions
AS participated in the design of the clinical trial, recruitment and treatment of the patients, data analysis and interpretation and manuscript preparation. JG and GB contributed to the data analysis and interpretation. NM and RH contributed to the design and implementation of the analysis of interoperator variability and dosimetric calculations. PB participated in the design of the dosimetric method used in the trial. JS contributed to the design of the trial and recruitment and treatment of the patients. ML contributed to the design of the dosimetric method and software used. JT participated in the design of the clinical trial, recruitment and treatment of patients and interpretation of data. KSG participated in the design of the dosimetric method and software, dosimetric calculations, data analysis and interpretation and manuscript preparation. All coauthors participated in the critical review of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Correspondence to Anna Sundlöv.
Ethics declarations
Authors’ information
This trial, and the present analysis, has been made possible through the close collaboration between oncologists (AS, JS, JT), physicists (KSG, PB, ML, GB, JG) and specialized technologists (NM, RH).
Ethics approval and consent to participate
The trial has been approved by the institutional ethics committee (Regionala Etikprövningsnämden Lund, ref. no. 2011/287) and national regulatory authorities. All patients signed an informed consent before inclusion in the trial.
Consent for publication
Through the informed consent form, the patients agreed to have their data published in group form in an anonymized manner.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Additional file
Additional file 1:
Table S1. Effective halftimes and absorbed doses for six patients in which both four SPECT/CT and four planar wholebody scans were acquired. AD: absorbed dose, L/R mean: mean absorbed dose between the left and right kidneys, Diff: % difference for L/R mean absorbed dose values calculated as (HybridSPECT)/SPECT. Table S2. Operator variability in estimated absorbed dose rate, effective halftime and absorbed dose. Op mean ± 1SD denotes the mean and standard deviation over the three operators, and L/R mean is the mean absorbed dose for the left and right kidneys. Upper rows: The notation of the three pharmacokinetic computer phantoms follow the notation used in (2). Uncertainty in absorbed dose is expressed as relative mean error (rE), relative standard deviation (rSD) and relative rootmean square error (rRMSE). Bottom rows: Results for patient studies with uncertainty expressed as the CV of the L/R mean. (DOCX 40 kb)
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Sundlöv, A., Gustafsson, J., Brolin, G. et al. Feasibility of simplifying renal dosimetry in ^{177}Lu peptide receptor radionuclide therapy. EJNMMI Phys 5, 12 (2018) doi:10.1186/s4065801802102
Received
Accepted
Published
DOI
Keywords
 PRRT
 Dosimetry
 Neuroendocrine
 177Lutetium
 Dotatate
 SPECT